BCAB vs BCTX

BioAtla, Inc. vs BriaCell Therapeutics Corp. — Valuation Comparison 2026

BCAB

Biotechnology
BioAtla, Inc.
Quality
3.4
out of 10
Value Trap
30
LOW
Price
$4.05
Last close
Models
7/13
Active
VS

BCTX

Biotechnology
BriaCell Therapeutics Corp.
Quality
4.5
out of 10
Value Trap
24
SAFE
Price
$3.58
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType BCAB Fair ValueBCAB Upside BCTX Fair ValueBCTX Upside
Bayesian DCF Intrinsic $1.80 -55.7% $3.26 -8.9%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.19 -95.5% $0.38 -91.0%
Dynamic NAV Asset-Based $22.05 +444.4% $7.83 +118.7%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for BCAB vs BCTX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

BCAB vs BCTX — Which Stock Is More Undervalued?

BCTX scores higher with a 4.5/10 quality rating vs BCAB's 3.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing BioAtla, Inc. (BCAB) and BriaCell Therapeutics Corp. (BCTX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

BCAB currently trades at $4.05 with a QOC of 3.4/10, while BCTX trades at $3.58 with a QOC of 4.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).